CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie dużokomórkowego chłoniaka B-komórkowego potwierdzonehistologicznie lub cytologicznie
- •Chłoniak wykazuje dodatnie białka CD19 i/lub CD22
- •Pełna remisja choroby po drugiej linii chemioterapii osiągnięta w ciągu ostatnich 3 miesięcy
- •Wiek od 18 do 85 lat
- •Dobry stan ogólny pacjenta (skala ECOG 0-2)
- •Przewidywana długość przeżycia powyżej 3 miesięcy
- •Wystarczające parametry krwi: hemoglobina ≥60 g/L, neutrofile ≥1000/μl, płytki ≥45000/μl
- •Obecność czynników ryzyka takich jak mutacje genetyczne lub zaawansowana postać chłoniaka
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chinese PLA General Hospital, Beijing, Beijing 100853
Beijing, China
Trial contact
Li-Ping Dou, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.